Glucocorticoids in Rheumatoid Arthritis
| Autor: | Margriet Huisman, Amalia A. Van Everdingen, Johannes W G Jacobs, Johannes W.J. Bijlsma, Ron N. J. de Nijs |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty business.industry General Neuroscience Treatment outcome Arthritis Early rheumatoid arthritis medicine.disease Gastroenterology General Biochemistry Genetics and Molecular Biology Endocrinology History and Philosophy of Science Glucocorticoid therapy Internal medicine Rheumatoid arthritis medicine In patient business Prospective cohort study hormones hormone substitutes and hormone antagonists Glucocorticoid medicine.drug |
| Zdroj: | Annals of the New York Academy of Sciences. 966:82-90 |
| ISSN: | 1749-6632 0077-8923 |
| DOI: | 10.1111/j.1749-6632.2002.tb04205.x |
| Popis: | Recently, four prospective placebo-controlled studies have further evaluated the disease-modifying properties of glucocorticoids in the treatment of rheumatoid arthritis. These studies irrefutably show that the use of (low) doses of glucocorticoids leads to a significant retardation of the progression of erosions, especially in early rheumatoid arthritis. This effect on erosions seems more impressive and probably more persistent than the well-known relief during low-dose glucocorticoid therapy of symptoms, such as pain, stiffness, and joint scores. The management of the (side) effects of glucocorticoids on bone has clearly improved in the last years. These two developments lead to a further optimizing of glucocorticoid treatment in patients with rheumatoid arthritis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text